CompletedPhase 2

Evaluation of the Bioavailability of Pramlintide

Lead sponsor

AstraZeneca

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight, Type 1 diabetes, Type 2 diabetes

Eligibility highlights

•BMI 30-45•HbA1c 6-12%

Primary endpoint

•Effect of varying needle length on bioavailability of Pramlintide

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00042471

Org study ID137-153

Timeline

Milestones

Study first posted2002-08-01estimated

Last update posted2015-09-23estimated

Study start2002-06 (month precision)

Primary completion2002-12actual (month precision)

Study completion2002-12actual (month precision)

Assets

Investigational agents

Pramlintide

Who this study enrolls

Obesity / overweightType 1 diabetesType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

•HbA1c value between 6-12%

•BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2

•Consistent insulin regimen for 2 months prior to screening

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint/low confidence

Effect of varying needle length on bioavailability of Pramlintide

Time frame:approximately 6days but not to exceed 14days

descriptive

Secondary/protocol endpoint

Effect of varying needle length on safety and tolerability of Pramlintide

Time frame:Approximately 6 days not to exceed 14days

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.